Mid-Cap Index Movement and Relative Performance

The mid-cap index recorded a marginally negative session, with the index edging lower by approximately 0.3% on 1 Feb 2026. This contrasted with the broader market’s modest gains, highlighting a relative underperformance in the mid-cap space. The segment’s performance was marked by a divergence between outperformers and laggards, reflecting investor selectivity amid ongoing macroeconomic uncertainties and sector-specific developments.

Among the mid-cap constituents, One 97 Communications stood out as the best performer, delivering a robust return of 5.00% during the session. This gain was supported by positive technical momentum and anticipation ahead of upcoming quarterly results. Conversely, National Aluminium Company (NALCO) emerged as the worst performer, declining by 8.88%, pressured by subdued commodity prices and weak demand outlook in the aluminium sector.

Sectoral Contributors and Headwinds

The mid-cap segment’s mixed performance was largely influenced by sectoral trends. The pharmaceutical and healthcare sectors showed resilience, buoyed by positive technical upgrades and improving fundamentals. Notably, Ajanta Pharma was upgraded from mildly bullish to bullish, reflecting growing investor confidence in its earnings trajectory and pipeline strength. Similarly, Star Health Insurance transitioned from a neutral stance to mildly bullish, supported by steady premium growth and improving claims ratios.

In the pharmaceutical space, Aurobindo Pharma shifted from a sideways trend to mildly bullish, signalling potential upside as the company benefits from increased export orders and regulatory approvals. These upgrades underscore a cautious optimism among market participants regarding mid-cap pharma stocks, which have historically been a key driver of segmental performance.

On the downside, commodity-linked sectors such as metals and mining faced headwinds. The sharp decline in NALCO’s stock price exemplifies the pressure from weak global aluminium prices and concerns over input cost inflation. This sectoral weakness contributed significantly to the overall drag on the mid-cap index.

Breadth Analysis Highlights Market Sentiment

Market breadth within the mid-cap universe was notably weak, with only 36 stocks advancing against 107 decliners, resulting in an advance-decline ratio of 0.34x. This lopsided breadth indicates a cautious or risk-averse stance among investors, with selling pressure concentrated in a large number of stocks despite pockets of strength.

The breadth data suggests that while select mid-cap stocks continue to attract buying interest, the majority are under pressure, reflecting concerns over earnings visibility, valuation levels, and broader macroeconomic factors. This uneven participation may limit the mid-cap index’s ability to sustain a meaningful rally in the near term.

Upcoming Earnings Announcements to Watch

Investor focus is also turning towards a series of mid-cap companies scheduled to declare quarterly results in the coming days. Key names include Honeywell Automation, Aarti Industries, Thermax, UPL, and PB Fintech, all set to report on 2 Feb 2026. Market participants will closely analyse these results for earnings surprises, margin trends, and guidance updates, which could influence mid-cap sentiment and index direction in the short term.

Technical Upgrades Signal Selective Optimism

Technical calls within the mid-cap space have seen some positive revisions recently, signalling pockets of selective optimism. Ajanta Pharma has been upgraded from mildly bullish to bullish, reflecting improved price momentum and volume patterns. Star Health Insurance moved from a neutral stance to mildly bullish, indicating a potential breakout in the near term. Meanwhile, Aurobindo Pharma has shifted from a sideways trend to mildly bullish, suggesting a possible upward trajectory.

These technical upgrades are important as they often precede fundamental re-rating and can attract institutional interest, potentially driving further gains in these stocks. However, investors should remain cautious given the broader market uncertainties and sector-specific challenges.

Outlook and Investor Considerations

Looking ahead, the mid-cap segment faces a challenging environment characterised by uneven sectoral performance and weak breadth. While pockets of strength in pharmaceuticals and healthcare offer selective opportunities, commodity-linked sectors may continue to face headwinds amid global price pressures. The upcoming earnings season will be critical in shaping investor sentiment, with results from key mid-cap companies likely to provide fresh cues on earnings momentum and margin sustainability.

Investors are advised to adopt a discerning approach, focusing on fundamentally strong mid-cap stocks with positive technical signals and robust earnings visibility. Diversification across resilient sectors and monitoring macroeconomic developments will be essential to navigate the current volatility in the mid-cap space.

In summary, the mid-cap index’s recent performance reflects a market in flux, with selective optimism tempered by broad-based caution. The segment’s trajectory will hinge on earnings outcomes, sectoral trends, and overall market sentiment in the weeks ahead.

Unlock special upgrade rates for a limited period. Start Saving Now →